Biotech · Private company
Escape Bio, Inc.
Track this companyFree. Adds Escape Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- G2019S LRRK2Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ObservationalPatients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) GeneClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Natural History Study of Patients With G2019S LRRK2 Parkinson's DiseaseTERMINATED · started May 2, 2022ClinicalTrials.gov NCT05349019 · fetched Nov 12, 2026
- Parkinson's Disease G2019S LRRK2 Genetic Testing ProgramTERMINATED · started Jun 8, 2021ClinicalTrials.gov NCT04919356 · fetched Nov 12, 2026